Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Seres Therapeutics Stock Scales Nasdaq on Positive Drug Data
05:39pm, Monday, 10'th Aug 2020
The stock hit a four-year high earlier in the day
Return On Capital Employed Overview: Seres Therapeutics
03:34pm, Monday, 10'th Aug 2020
During Q2, Seres Therapeutics (NASDAQ: MCRB) reported sales totaled $6.04 million. Despite a 4.33% in earnings, the company posted a loss of $20.55 million. In Q1, Seres Therapeutics brought in $8.19
This Tiny Biotech's Shares Quadruple After Late-Stage Drug Tests Succeed
02:39pm, Monday, 10'th Aug 2020
Seres Therapeutics early Monday announced Phase 3 success with its study of a treatment for a potentially fatal colon disease treatment, sending MCRB stock quadrupling in early trading.
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
12:27pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics Inc. undefined rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics...
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
12:27pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
10:30am, Monday, 10'th Aug 2020
SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
12:00am, Monday, 10'th Aug 2020
SER-109 met Phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of C. diff infection recurrence.
Banco de Chile (BCH) Q2 2020 Results - Earnings Call Transcript
11:29pm, Friday, 07'th Aug 2020
Banco de Chile (NYSE:BCH) Q2 2020 Earnings Conference Call August 07, 2020, 12:30 PM ET Company Participants Rodrigo Aravena - Chief Economist and Senior Vice President of Institutional Relations Pabl
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
12:55pm, Friday, 07'th Aug 2020
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Rhône-Alpes : comment ces 25 patrons continuent d'embaucher
08:56am, Thursday, 06'th Aug 2020
Capital a sondé pour vous les entreprises de la région Rhône-Alpes. En voici 25 qui, après avoir souvent adapté leur activité pendant le confinement, envisagent la reprise de leur développement
Seres Therapeutics Inc (NASDAQ:MCRB) Holdings Cut by Sumitomo Mitsui Trust Holdings Inc.
05:26am, Monday, 03'rd Aug 2020
Sumitomo Mitsui Trust Holdings Inc. decreased its stake in Seres Therapeutics Inc (NASDAQ:MCRB) by 12.1% in the second quarter, according to the company in its most recent filing with the Securities &
Seres Therapeutics (NASDAQ:MCRB) Downgraded by Zacks Investment Research
01:42am, Monday, 03'rd Aug 2020
Zacks Investment Research downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a sell rating in a research note released on Thursday, Zacks.com reports. According to Zacks, “Se
Research Analysts Offer Predictions for Seres Therapeutics Inc’s FY2020 Earnings (NASDAQ:MCRB)
02:14am, Sunday, 02'nd Aug 2020
Seres Therapeutics Inc (NASDAQ:MCRB) – Stock analysts at Jefferies Financial Group issued their FY2020 earnings estimates for Seres Therapeutics in a research note issued on Tuesday, July 28th. Jeff
Janus Henderson : Dividend/Distribution - JHG | MarketScreener
08:16am, Wednesday, 29'th Jul 2020Comment rédiger un CDI ?
08:12am, Wednesday, 29'th Jul 2020
La conclusion d’un contrat de travail à durée indéterminée demeure la forme typique et générale de la relation de travail.,
A cet égard, la rédaction d’un contrat de travail à durée ind
